StreetInsider.com News Articles

William Blair Starts Immunome Inc. (IMNM) at Outperform

Fri, 16 Oct 2026 02:52:30 -0400

William Blair analyst Alethia Young initiates coverage on Immunome Inc. (NASDAQ: IMNM) with a Outperform rating.

The analyst comments: “We are initiating coverage of Immunome with an Outperform rating and a DCF-based valuation of $35/share. Immunome is nearing its first approval with varegacestat, a gamma secretase inhibitor (GSI) for desmoid tumors, and is building a pipeline of first- and best-in class antibody-drug conjugates (ADCs). Much of the leadership team came from Seagen, which pioneered ADCs.

We think varegacestat becomes the dominant desmoid treatment, with ~ $1.4B in risk-adjusted sales five years after launch (2032) and helps fund the ADC engine, much like

William Blair Starts Immunome Inc. (IMNM) at Outperform

Fri, 16 Oct 2026 02:52:30 -0400

William Blair analyst Alethia Young initiates coverage on Immunome Inc. (NASDAQ: IMNM) with a Outperform rating.

We think varegacestat becomes the dominant desmoid treatment, with ~ $1.4B in risk-adjusted sales five years after launch (2032) and helps fund the ADC engine, much like

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 06 Oct 2026 16:02:00 -0400

BOTHELL, Wash.--(BUSINESS WIRE)--

Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a clinical-stage target oncology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on October 1, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 120,900 shares of common stock and 7,200 restricted stock units (“RSUs”) to ten new employees under the Company’s 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 06 Oct 2026 16:02:00 -0400

BOTHELL, Wash.--(BUSINESS WIRE)--

Immunome (IMNM) Reiterated at Hold by Stifel on Sensible License Cleanup With Bristol

Tue, 06 Oct 2026 07:48:39 -0400

Stifel analyst Dara Azar reiterated a Hold rating and $24.00 price target on Immunome Inc. (NASDAQ: IMNM).

The analyst commented, "we view IMNM’s agreement with Bristol a sensible license cleanup that can simplify discussions for varegacestat's ex-US commercialization. IMNM paid $20mm and issued ~4.43M common shares to eliminate remaining payment obligations to Bristol and acquire the previously licensed varegacestat patent rights. We think unencumbered economics should simplify potential partnership discussions if IMNM decides to pursue those at some point. That said, we would not interpret the agreement as a signal of a near-term transaction. Our base case is that several quarters

Form 8-K Immunome Inc. For: Oct 02

Mon, 05 Oct 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20261005/27146201.html

Stifel Starts Immunome Inc. (IMNM) at Hold

Wed, 30 Sep 2026 16:06:50 -0400

Stifel analyst Dara Azar initiates coverage on Immunome Inc. (NASDAQ: IMNM) with a Hold rating and a price target of $24.00.

The analyst comments "Varegacestat is a gamma-secretase inhibitor (GSI) under FDA review entering the quality-of-life-driven desmoid market over three years behind Ogsiveo (nirogacestat), the incumbent GSI, which we believe mapped the class opportunity. We find differentiation debatable on efficacy, pain and convenience, which exposes the launch further to incumbent, opportunity and next-class risks simultaneously. Rare-oncology second-in-class precedents set a bar we doubt varegacestat clears. The ADC side is where we want to be right, though requires more readouts. A proprietary

Stifel Starts Immunome Inc. (IMNM) at Hold

Wed, 30 Sep 2026 16:06:50 -0400

Stifel analyst Dara Azar initiates coverage on Immunome Inc. (NASDAQ: IMNM) with a Hold rating and a price target of $24.00.

FDA clears Immunome IND for IM-1340 solid tumor antibody-drug conjugate

Wed, 30 Sep 2026 07:47:41 -0400

Immunome, Inc. (Nasdaq: IMNM) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for IM-1340, an antibody-drug conjugate the company claims is a potential first-in-class therapy for advanced solid tumors.

IM-1340 targets a transport receptor expressed across multiple solid tumor types, including neuroendocrine tumors, lung cancer, and colorectal cancer. The drug incorporates HC74, Immunome's proprietary topoisomerase I inhibitor payload. Preclinical studies showed anti-tumor activity, including tumor regressions following a single dose across multiple in vivo models.

Immunome expects to initiate a Phase 1 clinical trial in the fourth quarter of 2026. The study is designed as

Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors

Wed, 30 Sep 2026 07:45:00 -0400

IM-1340 incorporates Immunome's proprietary HC74 topoisomerase I inhibitor payload and targets a transport receptor expressed across solid tumors, including neuroendocrine tumors, lung cancer, and colorectal cancer
Company expects to initiate Phase 1 first-in-human study in patients with advanced solid tumors in the fourth quarter of 2026
IM-1340 is Immunome’s fifth program in clinical development

BOTHELL, Wash.--(BUSINESS WIRE)--

Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for

Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors

Wed, 30 Sep 2026 07:45:00 -0400

IM-1340 incorporates Immunome's proprietary HC74 topoisomerase I inhibitor payload and targets a transport receptor expressed across solid tumors, including neuroendocrine tumors, lung cancer, and colorectal cancer
Company expects to initiate Phase 1 first-in-human study in patients with advanced solid tumors in the fourth quarter of 2026
IM-1340 is Immunome’s fifth program in clinical development

BOTHELL, Wash.--(BUSINESS WIRE)--

Alliance Global Partners Starts Immunome Inc. (IMNM) at Buy

Mon, 21 Sep 2026 07:08:21 -0400

Alliance Global Partners analyst Matthew Venezia initiates coverage on Immunome Inc. (NASDAQ: IMNM) with a Buy rating and a price target of $32.00.

For an analyst ratings summary and ratings history on Immunome Inc. click here. For more ratings news on Immunome Inc. click here.

Shares of Immunome Inc. closed at $23.97 yesterday.

Form 4 Immunome Inc. For: Sep 11 Filed by: Higgins Jack

Tue, 15 Sep 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260915/27065295.html

Form 144 Immunome Inc. Filed by: Higgins Jack

Fri, 11 Sep 2026 10:20:00 -0400

si-local-file:///var/storage/secattach/20260911/27051514.html

H.C. Wainwright Reiterates Buy Rating on Immunome Inc. (IMNM)

Fri, 11 Sep 2026 06:58:50 -0400

H.C. Wainwright analyst Andres Y. Maldonado reiterated a Buy rating and $40.00 price target on Immunome Inc. (NASDAQ: IMNM).

The analyst commented: "Ahead of IM-1021’s initial lymphoma readout later this year, we completed a deeper diligence effort around ROR1 biology, prior clinical experience with the target, and what we believe is the most differentiated component of IM-1021, its HC74 payload-linker design. Importantly, our KOL work was intentionally bifurcated between two perspectives, scientists actively conducting research on ROR1 biology and clinicians with meaningful experience using and evaluating ADCs, including ROR1-directed approaches. We think that distinction matters because the two groups approached the

Form SCHEDULE 13G/A Immunome Inc. Filed by: T. Rowe Price Investment Management, Inc.

Fri, 14 Aug 2026 10:40:00 -0400

si-local-file:///var/storage/secattach/20260814/26926665.html

Form SCHEDULE 13G/A Immunome Inc. Filed by: T. Rowe Price Investment Management, Inc.

Fri, 14 Aug 2026 10:40:00 -0400

si-local-file:///var/storage/secattach/20260814/26926665.html

Form SCHEDULE 13G/A Immunome Inc. Filed by: Sirenia Capital Management LP

Fri, 14 Aug 2026 08:34:00 -0400

si-local-file:///var/storage/secattach/20260814/26925210.html

Form SCHEDULE 13G/A Immunome Inc. Filed by: Sirenia Capital Management LP

Fri, 14 Aug 2026 08:34:00 -0400

si-local-file:///var/storage/secattach/20260814/26925210.html

Form 4 Immunome Inc. For: Aug 10 Filed by: Barchas Isaac

Wed, 12 Aug 2026 17:47:00 -0400

si-local-file:///var/storage/secattach/20260812/26914541.html

Form 4 Immunome Inc. For: Aug 10 Filed by: Barchas Isaac

Wed, 12 Aug 2026 17:47:00 -0400

si-local-file:///var/storage/secattach/20260812/26914541.html

Form 144 Immunome Inc. Filed by: Barchas Isaac

Wed, 12 Aug 2026 11:40:00 -0400

si-local-file:///var/storage/secattach/20260812/26911081.html

Form 144 Immunome Inc. Filed by: Barchas Isaac

Wed, 12 Aug 2026 11:40:00 -0400

si-local-file:///var/storage/secattach/20260812/26911081.html

Form 4 Immunome Inc. For: Aug 04 Filed by: Horn Kinney

Wed, 12 Aug 2026 11:03:00 -0400

si-local-file:///var/storage/secattach/20260812/26910791.html

Form 4 Immunome Inc. For: Aug 04 Filed by: Horn Kinney

Wed, 12 Aug 2026 11:03:00 -0400

si-local-file:///var/storage/secattach/20260812/26910791.html